openPR Logo
Press release

Ki67 as an additional marker on circulating tumor cells

02-24-2020 04:47 PM CET | Health & Medicine

Press release from: SIMFO GmbH

maintrac number of potential circulating tumor cells, Examination parameter, in the sample (1mm), in circulation (5l, in million)

maintrac number of potential circulating tumor cells, Examination parameter, in the sample (1mm), in circulation (5l, in million)

Ki67 is a nuclear protein that is associated with cell proliferation. Ki67 is present during all active phases of the growth cycle, but is absent in resting (quiescent) cells. Ki67 is identified with the IHC method. The presence of Ki67 protein on circulating tumor cells indicates the percentage of circulating tumor cells in the active growth phase of the cell cycle. Higher amounts are associated with an increased risk of progression or recurrence.

Circulating tumor cells and ki67 together provide a very useful tool in monitoring treatment effectiveness and risk of proogression of disease.

An interesting article regarding KI67:
Mavroudis D., Agelaki S. Jounal of Clinical Oncology,34,15.2017 - Association of Ki-67 expression in CTCs with disease relapse ...

High Ki67 expression - increased risk of progression

The two examples are from patients following initial surgery of the primary tumour plus adjuvant treatment. The identified number of circulating tumor cells is low, but the Ki67 expression is high, indicating an increased risk of progression.

Closer monitoring with circulating tumor cells count and clinical assessment are indicated here.

Further information:

Peter Pachmann
Kurpromenade 2
95448 Bayreuth
T: 092173005210

Maintrac is an innovative analysis platform in cancer diagnostics and therapy monitoring. Maintrac identifies and quantifies the circulating tumor cells in the blood sample of cancer patients and analyzes the efficacy of selected drugs. In clinical trials with more than 900 patients, maintrac has demonstrated that monitoring circulating tumor cells in the adjuvant situation, during maintenance and antibody therapy in breast cancer has significant benefits. Possible relapses can be recognized at an early stage.

The research and development company SIMFO offers professional study management, drug development in connection with the highest know-how in oncology, hemostaseology, and transfusion medicine. Constant training, structured knowledge transfer and a successful innovation culture are the basis for SIMFO to develop the most modern top-class procedures.

SIMFO GmbH is an independent private company doing research, contract research and development, not providing any drugs or therapies. Maintrac is a tool to provide physicians with a decision aid for therapy options by monitoring and sensitivity testing of circulating tumor cells.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Ki67 as an additional marker on circulating tumor cells here

News-ID: 1942530 • Views:

More Releases from SIMFO GmbH

Antithrombotic management plan for cancer patients
In Germany Thrombosis occurs 470.000 timesevery year - as often as a new cancer is diagnosed. With 44.000 deadly lung artery embolisms every year, thrombosis is very dangerous. Around 30 independent risk factors are known. One of the more important risk factors seems to be the amount of intracirculatory tissue factor molecules which is brought into circulation bound to the circulating epithelial cells. Tissue factor is always active to start the

More Releases for Ki67

HER2+ Breast Cancer Market Report- COVID-19 Impact | Global Drug Forecast and Ma …
The HER2+ Breast Cancer Market research report gives a 360-degree perspective by looking at political, social, money-related, and innovative progressions boosting the market development. HER2+ Breast Cancer Market also covers the rising assessment of market development and provides comprehensive information about all changes and dangers identified with the worldwide HER2+ Breast Cancer Market during the projected period. In addition, the HER2+ Breast Cancer Market research report covers every one of
HER2+ Breast Cancer Market Report- Strengths of Analysis and Epidemiological For …
HER2+ Breast Cancer Market report firstly introduces the HER2+ Breast Cancer Market basics: definitions, classifications, applications, and market overview, product Specifications, manufacturing Processes, cost structures, raw materials, and much more. HER2+ Breast Cancer Market analyzes other vital factors like product cost, capacity, benefit, supply, request, advertise development rate, estimate, etc. Finally, HER2+ Breast Cancer Market report concludes by presenting SWOT analysis, speculation possibility analysis, and speculation return analysis. Get FREE
Washington D.C., USA – Royal Philips Electronics (NYSE: PHG, AEX: PHI) and Definiens, a Germany-based company specializing in image analysis solutions, today announced that they have signed a memorandum of understanding to jointly develop and market clinical decision support solutions for digital pathology. Leveraging its expertise in medical imaging and healthcare informatics solutions (e.g. radiology Picture Archiving and Communications Systems (PACS)), Philips is committed to delivering highly integrated solutions for